3.1 Drug Classifications, Interactions, and Cross-Tolerance

Why pharmacology belongs on the ADC exam

The IC&RC Alcohol and Drug Counselor (ADC) Examination weights Domain I: Scientific Principles of Substance Use and Co-Occurring Disorders at 25% of scored content. Task I.D.1 in the ADC Candidate Guide (effective November 2022; PDF posted July 2025 at https://internationalcredentialing.org/wp-content/uploads/2025/07/ADC-Candidate-Guide-2022.pdf, checked 2026-09-20) asks candidates to differentiate common substances by pharmacology, including drug classifications, interactions, and cross-tolerance. This section is independent ADC study material by OpenExamPrep. OpenExamPrep does not claim IC&RC approval, partnership, or exact equivalence with IC&RC courseware. Official item writing, scoring, and candidate rules remain IC&RC and member-board products.

You will not be scored on writing a prescription. You will be scored on whether you can explain why a fifth-a-day drinker may look only mildly sedated after a benzodiazepine dose that would drop a naive adult, why alcohol plus an opioid is not two harmless nightcaps, and why naloxone reverses an opioid overdose but does nothing to a pure alcohol coma.

At Northbridge Recovery Center, counselor Dana Ellis completes intake with Marcus, age 42. He drinks roughly a fifth of vodka most days, swallows alprazolam borrowed from a cousin to take the edge off, and for ten days has taken leftover oxycodone after a dental extraction. He reports that none of it does much anymore. Domain I.D.1 is the vocabulary Dana needs before she ever writes a treatment plan.

Clinical classification: uppers, downers, and all-arounders

Many counselor texts sort psychoactive drugs into uppers (central nervous system, or CNS, stimulants), downers (CNS depressants), and all-arounders (drugs that distort perception—cannabis, classic hallucinogens, and many dissociatives). That map is useful on the unit. The exam also expects pharmacologic class: the receptor or transporter the drug primarily hits. Class predicts intoxication, overdose, withdrawal, and which combinations stack.

Trap: treating every downer as the same pharmacology. Alcohol, benzodiazepines, and barbiturates move GABA-A in the same direction. Opioids also depress the CNS, but they act at opioid receptors, not as GABA-A positive modulators. That split decides cross-tolerance items here and which withdrawal can kill in section 3.3.

Receptor actions: agonist, partial agonist, antagonist

A receptor is a protein a drug binds. The action is what happens next.

• A full agonist binds and produces a near-maximal effect. At the mu receptor that includes heroin, fentanyl, morphine, oxycodone, and methadone.
• A partial agonist binds and produces a ceiling lower than a full agonist. Buprenorphine is a high-affinity partial mu agonist and a kappa antagonist. The ceiling is why respiratory depression plateaus relative to fentanyl at high dose. High affinity is why buprenorphine can precipitate withdrawal if it knocks a full agonist off mu receptors while that agonist is still on board.
• An antagonist occupies the receptor and blocks agonists without turning the receptor on. Naloxone is a short-acting competitive mu antagonist used to reverse opioid overdose. Naltrexone is a longer-acting antagonist used in planned relapse-prevention pathways (oral or extended-release), not as the usual field rescue spray.

Worked Northbridge example: Marcus still has oxycodone in his system. A roommate gives him a large first strip of buprenorphine to help him stop. Within minutes he is yawning, sweating, vomiting, and covered in gooseflesh. That is precipitated opioid withdrawal—receptor occupancy—not an allergy.

Trap: calling naltrexone the street-rescue antagonist. Community kits are naloxone (intranasal or injectable). Naltrexone also occupies mu receptors and can precipitate withdrawal, but counseling uses it as planned blockade after an opioid-free window. Another trap: calling buprenorphine a full opioid interchangeable with methadone. Both appear in medication-for-addiction-treatment discussions later in this guide; the receptor math is not the same.

Pharmacokinetic versus pharmacodynamic interactions

An interaction is any change in effect when two substances are present.

Pharmacokinetic (PK) interactions change how much drug reaches the target: absorption, distribution, metabolism, or excretion (often remembered as ADME). Examples Dana uses in psychoeducation:

• Chronic heavy alcohol use induces cytochrome P450 2E1 (CYP2E1), which can increase conversion of acetaminophen to a hepatotoxic metabolite—relevant when Marcus lives on extra-strength acetaminophen for hangovers.
• Several benzodiazepines (including alprazolam) and many opioids are CYP3A4 substrates. Strong inhibitors can raise blood levels; inducers can drop them.
• Cirrhosis, aging, and first-pass metabolism change levels without changing the receptor itself.

Pharmacodynamic (PD) interactions change what the drugs do together at tissues, even if each concentration is unchanged. Alcohol plus a benzodiazepine is the ADC prototype: both increase GABA-A inhibitory tone. The result is synergistic CNS depression—combined impairment and overdose risk greater than one drink plus one pill. Alcohol plus an opioid stacks two depressant systems (GABA/glutamate disruption plus mu-mediated reduction of respiratory drive). Benzodiazepine–opioid pairs carry the same PD warning: additive and synergistic respiratory depression.

Marcus's triad—vodka, alprazolam, oxycodone—is a PD emergency in slow motion, not a clever self-taper. Dana names the combination, teaches without shaming, and coordinates with medical staff. She does not tell him to just skip the benzo tonight as if that were a monitored detox plan.

Cross-tolerance: alcohol and benzodiazepines

Tolerance means a larger dose is required for the same effect, or the same dose produces less effect. Cross-tolerance means tolerance to drug A reduces response to drug B because they share a mechanism.

The pairing ADC candidates must not miss is cross-tolerance between alcohol and benzodiazepines. Both facilitate GABA-A receptor function. A brain adapted to daily ethanol is also adapted to benzodiazepines. That is why:

1. Marcus may swallow several alprazolam tablets and still look only buzzed.
2. Alcohol-withdrawal protocols often use benzodiazepines: they can substitute at GABA-A and blunt autonomic hyperactivity and seizures (cross-dependence).
3. A client who never takes pills but drinks a handle weekly is not benzodiazepine-naive in GABA terms.

Cross-tolerance also runs among benzodiazepines, barbiturates, and other sedative-hypnotics that hit GABA-A. It does not classically pair alcohol with cannabis (CB1), amphetamines (monoamine releasers or reuptake blockers), or opioids (mu receptors) as the textbook GABA example. Opioids and alcohol both depress the CNS and can kill together; that is synergistic PD depression, not the same fact as GABA-A cross-tolerance.

Reverse tolerance (sensitization), described with some stimulant patterns, is the opposite direction: less drug, more effect. Do not drop that term into an alcohol–benzo stem.

Dana's family-night sentence: alcohol and benzodiazepines press the same brain brake. Using both is two feet on one pedal. Over time the pedal gets harder to push. When you stop, the brain can slam into overdrive.

Classification and interaction traps

1. Equating opioid downers with alcohol and benzodiazepine GABA-A pharmacology.
2. Naming cannabis, amphetamines, or opioids as alcohol's cross-tolerance partner on a GABA item.
3. Calling buprenorphine a full mu agonist, or calling naloxone the long-acting relapse-prevention antagonist (that role is naltrexone).
4. Labeling alcohol plus a benzodiazepine as only pharmacokinetic because the liver processes both.
5. Assuming a client who denies pill problems cannot have benzodiazepine cross-tolerance if they drink daily.
6. Treating independent OpenExamPrep practice as an IC&RC-published exam form.